Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, child: Other
Stage/Subtype:  recurrent childhood brain tumor
Trial Type:  Treatment
Results 1-25 of 39 for your search:
Start Over
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 30
Trial IDs: SOL-08131-L, NCI-2013-00790, 5056, MR00042551, OHSU-5056, NCT00983398
Selumetinib in Treating Young Patients with Recurrent or Refractory Low Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: PBTC-029B, NCI-2012-03173, CDR667932, PBTC-029, NCT01089101
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Radiation Therapy in Treating Patients With Recurrent or Progressive Brain Stem Glioma Previously Treated With Radiation Therapy
Phase: Phase II, Phase I
Type: Treatment
Age: 17 and under
Trial IDs: 2011-0804, NCI-2011-03725, NCT01469247
Rituximab in Treating Patients with Relapsed or Refractory Lymphoid Malignancies Involving the Central Nervous System
Phase: Phase II, Phase I
Type: Treatment
Age: 3 and over
Trial IDs: 2011-0844, NCI-2012-00849, NCT01596127
WEE1 inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1312, NCI-2014-00547, NCT02095132
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: V0706, NCI-2014-00478, NCT00601003
Everolimus in Treating Younger Patients With Neurofibromatosis Type 1 or Low Grade Gliomas That Did Not Responded to Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 09452, NCI-2010-01929, DOD W81XWH-05-1-0615, NCT01158651
Poly ICLC in Treating Younger Patients With Recurrent or Progressive Low Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: Poly-ICLC, NCI-2013-02084, NCT01188096
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients with Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 22
Trial IDs: ACNS1022, NCI-2012-00703, CDR0000728296, COG-ACNS1022, NCT01553149
Everolimus in Treating Younger Patients With Recurrent or Progressive Low-Grade Gliomas
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Age: 3 to 21
Trial IDs: 120817, NCI-2012-02774, PNOC001, NCT01734512
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Surgery and Second-Course Radiation Therapy in Treating Younger Patients with Recurrent Ependymoma
Phase: Phase II
Type: Treatment
Age: 1 to 21
Trial IDs: RERTEP, NCI-2014-00906, NCT02125786
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: AFLACST1502, NCI-2015-01637, IRB00082488, NCT02574728
Crizotinib and Dasatinib in Treating Younger Patients with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma or High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 21
Trial IDs: SJHG12, NCI-2012-01240, NCT01644773
Melphalan in Treating Patients with Progressive Diffuse Intrinsic Pontine Gliomas
Phase: Phase I
Type: Treatment
Age: 1 month to 17 years
Trial IDs: J11164, NCI-2013-00515, NA_00069122, NCT01688401
Oncolytic HSV-1716 in Treating Younger Patients with Refractory or Recurrent High Grade Glioma That Can Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 21
Trial IDs: PBTC-037, NCI-2013-00526, NCT02031965
Palbociclib Isethionate in Treating Younger Patients with Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: PBTC-042, NCI-2014-00640, NCT02255461
Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1414, NCI-2014-02410, NCT02323880
Pomalidomide in Treating Younger Patients with Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 20
Trial IDs: PBTC-043, NCI-2014-02182, CC-4047-PBTC-043, PPBTC-043_R04PAPP01, NCT02415153
Start Over